SCHEMBL6797635

SCHEMBL6797635

CCN1CCc2cc(/C=C3\SC(=S)N(CCS(=O)(=O)O)C3=O)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
KMT2A Q03164 3/20 0.45
LMNA P02545 2/20 0.45
PSMD14 O00487 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PDE4B Q07343 2/20 0.45
DUSP3 P51452 2/20 0.45
MAPT P10636 2/20 0.44
MEN1 O00255 2/20 0.44
POLB P06746 2/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 1/20 0.44
BLM P54132 1/20 0.44
MCL1 Q07820 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
APP P05067 1/20 0.44
MYC P01106 1/20 0.43
MAX P61244 1/20 0.43
HSD17B3 P37058 1/20 0.43
MAOA P21397 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6797642 1.00 ALDH1A1 (0.45) ALDH1A1KMT2ALMNAPSMD14SMN1; SMN2
SCHEMBL11978759 0.86 FABP4 (0.58) ALDH1A1KMT2ALMNAPSMD14SMN1; SMN2
SCHEMBL11978766 0.84 PTPN12 (0.56) KMT2APSMD14PDE4BMAPTMEN1
SCHEMBL21414955 0.80 MAPT (0.43) ALDH1A1KMT2ALMNAPSMD14SMN1; SMN2
SCHEMBL13170354 0.79 PTPN12 (0.57) KMT2APSMD14PDE4BMAPTMEN1
SCHEMBL6791405 0.78 MEN1 (0.43) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL6791395 0.78 MEN1 (0.43) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL6475605 0.77 PTPN12 (0.53) ALDH1A1KMT2APDE4BMAPTMEN1
SCHEMBL6474686 0.77 PTPN12 (0.53) ALDH1A1KMT2APDE4BMAPTMEN1
SCHEMBL13170392 0.76 PTPN12 (0.51) ALDH1A1KMT2APDE4BMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-10-07 US disclosed
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 EP disclosed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives APP, PSEN1, PSEN2 ALDH1A1 1741/4885KMT2A 4348/4885LMNA 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.